 Dengue
> Follow-up |
Author: Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath; Panduka Karunanayake, MD, MRCP; Bandula Wijesiriwardena, MD, FRCP, FCCP,
FCMSA, FRACP, FACP
Editorial changes - 2009-11-13
Author information and module status |
|
 |
|
|
 |
|
Rationale:
- Various sequelae, including anorexia, joint and muscle pain, and fatigue, have been noted after resolution of an acute dengue
infection.
- Convalescence may be prolonged for weeks because of asthenia and depression.
|
|
Evidence:
- Postinfectious complications were common among 26 patients with serologically confirmed dengue fever diagnosed in Norway between
1991 and 1996. Four weeks after the acute illness, hair loss, depression, and asthenia were reported by 45%, 50%, and 100%
of patients, respectively (45).
- A follow-up telephone interview was conducted 2 months after hospital discharge and a fatigue questionnaire was administered
in 127 patients with serologically confirmed dengue infection admitted to the National University Hospital in Singapore during
a dengue outbreak from October to November 2005. Twenty-five patients (19.7%) had dengue hemorrhagic fever, and 102 patients
(80.3%) had dengue fever. In multivariate analysis, increased age, female sex, the presence of chills, and the absence of
rashes were significantly associated with the development of fatigue after dengue infection. No significant association was
found between fatigue and dengue severity (117).
|
|
Comments:
|
| FAQs |
|
|
|
Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Panduka Karunanayake, MD, MRCP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
